Last reviewed · How we verify
NCT05097664
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
trial in COVID-19 in 250 participants. Status unknown.
21 November 2021
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 23 August 2021 |
| Primary completion | 21 November 2021 |
| Estimated completion | 20 January 2022 |
| Sites | 1 location across Iran |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Mucormycosis — all drugs for Mucormycosis →
Sponsor
Isfahan University of Medical Sciences
Who can join
Eligibility, any sex, with COVID-19 or Mucormycosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.
Eshraghi B, Khademi B, Mirmohammadkhani M, Khataminia G, et al · · 2024 · cited 8× · PMID 39174954 · DOI 10.1186/s12879-024-09755-6 -
One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study.
Eshraghi B, Khademi B, Bahmani Kashkouli M, Khataminia G, et al · · 2025 · cited 1× · PMID 40619554 · DOI 10.1007/s11046-025-00966-2 -
Collaborative Study of COVID-19 Associated Rhino- Orbital-Cerebral Mucormycosis in Iran (CA-ROCM-IR): A Preliminary Report
Eshraghi B, Khademi B, Mirmohammadkhani M, Khataminia G, et al · · 2023 · cited 1× · DOI 10.21203/rs.3.rs-2495890/v1
Verify or expand the search:
- PubMed search for NCT05097664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05097664 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 28 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05097664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing